| Drug Name |
Bleomycin sulfate |
| Drug ID |
BADD_D00281 |
| Description |
A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin. |
| Indications and Usage |
For palliative treatment in the management malignant neoplasm (trachea, bronchus, lung), squamous cell carcinoma, and lymphomas. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01DC01 |
| DrugBank ID |
DB00290
|
| KEGG ID |
D02177
|
| MeSH ID |
D001761
|
| PubChem ID |
72466
|
| TTD Drug ID |
D06UVD
|
| NDC Product Code |
71288-107; 58623-0033; 63323-136; 63323-137; 53183-7003; 71288-106 |
| UNII |
7DP3NTV15T
|
| Synonyms |
Bleomycin | Bleomycins | BLEO-cell | BLEO cell | BLEOcell | Bleolem | Bléomycine Bellon | Bellon, Bléomycine | Bleomycin A2 | Bleomycin A(2) | Bleomycin B2 | Bleomycin B(2) | Bleomycin Sulfate | Sulfate, Bleomycin | Bleomycinum Mack | Mack, Bleomycinum | Blenoxane | Blanoxan | Bleomicina |
